Insider Transactions in Q3 2021 at Adagio Therapeutics, Inc. (ADGI)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 10
2021
|
Adimab, LLC |
BUY
Conversion of derivative security
|
Direct |
25,860,700
+48.15%
|
-
|
|
Aug 10
2021
|
Tillman U. Gerngross Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,860,700
+48.15%
|
-
|
|
Aug 10
2021
|
Terrance Mcguire |
BUY
Open market or private purchase
|
Indirect |
500,000
+9.81%
|
$8,500,000
$17.0 P/Share
|
|
Aug 10
2021
|
Terrance Mcguire |
BUY
Conversion of derivative security
|
Indirect |
8,031,700
+50.0%
|
-
|
|
Aug 10
2021
|
Mithril Ii LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,997,000
+15.08%
|
$33,949,000
$17.0 P/Share
|
|
Aug 10
2021
|
Mithril Ii LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
9,244,580
+50.0%
|
-
|
|
Aug 10
2021
|
Ajay Royan Director |
BUY
Open market or private purchase
|
Indirect |
1,997,000
+15.08%
|
$33,949,000
$17.0 P/Share
|
|
Aug 10
2021
|
Ajay Royan Director |
BUY
Conversion of derivative security
|
Indirect |
9,244,580
+50.0%
|
-
|
|
Aug 10
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,470,000
+30.24%
|
$24,990,000
$17.0 P/Share
|
|
Aug 10
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,920,960
+50.0%
|
-
|